Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Mereo BioPharma Group Filed by: BANK OF AMERICA CORP /DE/

May 14, 2026 3:08 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: "1. The security CUSIP corresponds to Mereo Biopharma Group PLC CUSIP International Numbering System (CINS) of the common stock. 2. The beneficial ownership calculation relies on the 798,078,829 outstanding shares disclosed in the Form 10-K by the issuer on March 19, 2026, which reports share totals as of March 18, 2026."


SCHEDULE 13G



BANK OF AMERICA CORP /DE/
Signature:/s/ Monica Yako
Name/Title:Authorized Signatory
Date:05/14/2026

ATTACHMENTS / EXHIBITS

POWER OF ATTORNEY

Categories

SEC Filings